WO2020101361A1 - 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 - Google Patents
형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 Download PDFInfo
- Publication number
- WO2020101361A1 WO2020101361A1 PCT/KR2019/015469 KR2019015469W WO2020101361A1 WO 2020101361 A1 WO2020101361 A1 WO 2020101361A1 KR 2019015469 W KR2019015469 W KR 2019015469W WO 2020101361 A1 WO2020101361 A1 WO 2020101361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- gene
- natural killer
- mbil
- seq
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 153
- 238000000034 method Methods 0.000 title claims abstract description 63
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 62
- 238000012258 culturing Methods 0.000 title claims abstract description 61
- 210000004700 fetal blood Anatomy 0.000 title claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims abstract description 309
- 108090000623 proteins and genes Proteins 0.000 claims description 135
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 64
- 210000005087 mononuclear cell Anatomy 0.000 claims description 41
- 108010042215 OX40 Ligand Proteins 0.000 claims description 39
- 108010002350 Interleukin-2 Proteins 0.000 claims description 26
- 102000000588 Interleukin-2 Human genes 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 241000713666 Lentivirus Species 0.000 claims description 10
- 108010074108 interleukin-21 Proteins 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 8
- 102000003812 Interleukin-15 Human genes 0.000 claims description 7
- 108090000172 Interleukin-15 Proteins 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000012136 culture method Methods 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 102000003810 Interleukin-18 Human genes 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- 229940127174 UCHT1 Drugs 0.000 claims description 2
- 230000022534 cell killing Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 56
- 238000010586 diagram Methods 0.000 description 45
- 239000002609 medium Substances 0.000 description 44
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 36
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 34
- 230000004083 survival effect Effects 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 22
- 230000035755 proliferation Effects 0.000 description 22
- 210000003954 umbilical cord Anatomy 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 19
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 17
- 210000001616 monocyte Anatomy 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 230000009261 transgenic effect Effects 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000029791 ADAM Human genes 0.000 description 8
- 108091022885 ADAM Proteins 0.000 description 8
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 7
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 102100038077 CD226 antigen Human genes 0.000 description 6
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 6
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 6
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 102000043279 ADAM17 Human genes 0.000 description 5
- 108091007505 ADAM17 Proteins 0.000 description 5
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 5
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- -1 mbIL-21 Proteins 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940087463 proleukin Drugs 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- LXKCHCXZBPLTAE-UHFFFAOYSA-N 3,4-dimethyl-1H-pyrazole phosphate Chemical compound OP(O)(O)=O.CC1=CNN=C1C LXKCHCXZBPLTAE-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to a method for culturing natural killer cells derived from umbilical cord blood using transformed T cells.
- an immunotherapy method using a patient's immune function has been developed.
- immunotherapies using natural killer cells capable of mass production and freezing are being studied.
- Natural killer cells are lymphocyte cells that account for about 15% of peripheral blood lymphocytes and play an important role in the innate immune response.
- natural killer cells activate dendritic cells and induce cytotoxic T lymphocytes (CTLs) to specifically respond to tumors, thereby removing tumor cells.
- CTLs cytotoxic T lymphocytes
- Natural killer cells directly kill malignant tumors such as sarcoma, myeloma, carcinoma, lymphomas and leukemia.
- malignant tumors such as sarcoma, myeloma, carcinoma, lymphomas and leukemia.
- most natural killer cells present in the normal human body exist in an inactive state, and activated natural killer cells are required to remove the tumor.
- natural killer cells in order to use natural killer cells as a therapeutic agent, it is very important to activate natural killer cells.
- the number of natural killer cells present in the body is limited, it is essential to develop a technique for proliferating and freezing natural killer cells in normal human blood or patient blood in large quantities.
- In vitro expansion method is used as a method for multiplying natural killer cells, and peripheral blood lymphocyte (PBMC), cord blood (CB), or human-induced pluripotent stem cell) is being studied for mass cultivation of natural killer cells.
- PBMC peripheral blood lymphocyte
- CB cord blood
- human-induced pluripotent stem cell human-induced pluripotent stem cell
- umbilical cord blood can be obtained through simple procedures from umbilical cord blood that is discarded during delivery, unlike bone marrow.
- the storage industry of cord blood has been activated, and it is easy to obtain a donor, and research into a method for culturing natural killer cells using cord blood has been actively conducted.
- in vitro expansion culture methods of umbilical cord blood-derived natural killer cells include proliferation using mononuclear cells (MNC) as source cells, and proliferation using hematopoietic progenitor cells (CD34 + cells) as source cells.
- MNC mononuclear cells
- CD34 + cells hematopoietic progenitor cells
- the method of using mononuclear cells as a source cell is to use interleukin-2 (IL-2), interleukin-15 (IL-15), or FLT-3L alone or in combination to help spawn natural killer cells, but proliferation rate and purity.
- IL-2 interleukin-2
- IL-15 interleukin-15
- FLT-3L alone or in combination to help spawn natural killer cells, but proliferation rate and purity.
- the method using hematopoietic progenitor cells as a raw material has a high proliferation rate and high purity, but has a long incubation period and needs to be mixed with various cytokines and growth factors, making it difficult to commercialize in terms of cost (Fias AM et al ., Experimental Hematology 36 (1): 61-68, 2008).
- PBMC In vitro expansion culture of natural killer cells, PBMC, CD3- cells, CD3-CD56 + cells, and CD56 + cells are used as raw cells, and IL-2, IL-12, IL-15, IL-21 are natural killer cell proliferation factors.
- Cytokines and LPS Goodier et al ., J. Immunol . 165 (1): 139-147, 2000
- CD3 stimulating OKT-3 antibody Condiotti et al., Experimental Hematol. 29 (1) : 104-113, 2001.
- Natural killer cells can be proliferated about 3 to 10 times only with the aforementioned growth factors. However, the proliferation rate is difficult to commercialize natural killer cells as therapeutic agents.
- Peripheral blood mononuclear cells, EBV-LCL, and K562 cell lines are typical cell lines used as support cells.
- the K562 cell line is a blood cancer-derived cell line that lacks HLA and is a representative target cell line that natural killer cells can easily attack.
- Most supporting cells that cultivate natural killer cells express and proliferate by expressing 4-1BBL and membrane-bound IL-15 in the K562 cell line ( Fujisaki et al ., Cancer Res. 69 (9): 4010 -4017, 2009), MICA, 4-1BBL, and a method of expressing and proliferating IL-15 (Gong et al.
- the present inventors proliferate in vitro by co-culturing CD4 + T cells expressing co-stimulatory factor and growth factor and natural killer cells derived from umbilical cord blood to efficiently proliferate natural killer cells from umbilical cord blood.
- the method was developed.
- the present inventors have produced transformed CD4 (+) T cells to increase the efficiency of the natural killer cell culture method using the CD4 (+) T cells as support cells.
- the transformed CD4 (+) T cells and umbilical cord blood-derived monocytes were co-cultured, and the present invention was completed by confirming that the proliferation rate and apoptosis ability of natural killer cells were increased through the co-culture.
- One aspect of the present invention provides a method for culturing natural killer cells comprising the step of co-culturing the transformed CD4 + T cells and the source cells.
- Another aspect of the present invention provides a natural killer cell prepared by the culture method.
- the method for culturing natural killer cells using the transformed T cells of the present invention can be produced by effectively proliferating natural killer cells from a small amount of raw cells derived from umbilical cord blood.
- the natural killer cells prepared as described above have improved cell killing ability. Therefore, the method for culturing natural killer cells using the transformed T cells of the present invention can be usefully used for commercialization of cell therapy products.
- natural killer cells produced by the culture method of the present invention can be usefully used as a cell therapy agent.
- 1A is a diagram confirming whether a gene is expressed in a Hut78 cell line through FACS.
- Figure 1b is a diagram confirming whether the expression of a single gene introduced into the Hut78 cell line through FACS.
- Figure 1c is a diagram confirming whether the expression of mTNF- ⁇ / OX40L and mTNF- ⁇ / 4-1BBL dual genes introduced into the Hut78 cell line through FACS.
- Figure 1d is a diagram confirming whether the expression of the mbIL-21 / OX40L and mbIL-21 / 4-1BBL dual genes introduced into the Hut78 cell line through FACS.
- Figure 1e is a diagram confirming whether the expression of the triple gene introduced into the Hut78 cell line through FACS.
- Figure 1f is a diagram confirming whether or not the expression of the quadruple gene introduced into the Hut78 cell line through FACS.
- Figure 2a is a diagram showing the proliferation rate of natural killer cells produced by co-culturing the CD3 (-) mononuclear cells derived from umbilical cord blood and the Hut78 cell line into which the gene has been introduced by each gene.
- Figure 2b is a diagram showing the proliferation rate of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 2c is a diagram showing the proliferation rate of natural killer cells prepared by co-culturing the gene-introduced Jurkat cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 2d is a diagram showing the proliferation rate of spontaneous killer cells prepared by co-culturing a CD3 (-) mononuclear cell derived from cord blood with a Peer cell line into which the gene has been introduced, by introduction gene.
- Figure 2e is a diagram showing the proliferation rate of natural killer cells prepared by re-stimulation at intervals of 14 or 16 days when co-culturing CD3 (-) monocytes derived from umbilical cord blood and Hut78 cell line in which the triple gene is introduced.
- Figure 3a is a diagram showing the survival rate of natural killer cells produced by co-culturing the CD3 (-) monocytes derived from umbilical cord blood and the Hut78 cell line with the gene introduced by each gene.
- Figure 3b is a diagram showing the survival rate of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord-derived CD3 (-) monocytes by gene.
- Figure 3c is a diagram showing the survival rate of natural killer cells prepared by co-culturing the gene-introduced Jurkat cell line and umbilical cord-derived CD3 (-) mononuclear cells for each gene.
- Figure 3d is a diagram showing the survival rate of spontaneous killer cells prepared by co-culturing CD3 (-) mononuclear cells derived from umbilical cord blood and the introduced Peer cell line by gene.
- Figure 3e is a diagram showing the survival rate of natural killer cells prepared by re-stimulation at intervals of 14 or 16 days when co-culturing CD3 (-) monocytes derived from umbilical cord blood and Hut78 cell line with triple gene introduction.
- FIG. 4A is a diagram showing the purity (CD3-CD56 +) of natural killer cells prepared by co-culturing a gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- 4B is a diagram showing the purity (CD3-CD56 +) of natural killer cells prepared by co-culturing a gene-introduced H9 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 4c is a diagram showing the purity (CD3-CD56 +) of the natural killer cells prepared by co-culturing the gene-introduced Jurkat cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 4d is a diagram showing the purity (CD3-CD56 +) of the natural killer cells prepared by co-culturing CD3 (-) mononuclear cells derived from umbilical cord blood and the introduced Peer cell line.
- Figure 4e is a diagram showing the purity (CD3-CD56 +) of natural killer cells prepared by re-stimulation at intervals of 14 or 16 days when co-culturing CD3 (-) monocytes derived from umbilical cord blood and Hut78 cell line with triple gene introduction to be.
- FIG. 5A is a diagram showing the activity (CD16 + CD56 +) of natural killer cells produced by co-culturing a gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- 5B is a diagram showing the expression level of the NKG2D phenotypic marker of natural killer cells produced by co-culturing a gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 5c is a diagram showing the expression level of the NKp30 phenotype marker of natural killer cells prepared by co-culturing the gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- 5D is a diagram showing the expression level of the NKp44 phenotype marker of natural killer cells produced by co-culturing the gene-introduced Hut78 cell line and umbilical cord blood-derived CD3 (-) monocytes by gene.
- Figure 5e is a diagram showing the expression level of the NKp46 phenotype marker of natural killer cells prepared by co-culturing the gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 5f is a diagram showing the expression level of the DNAM-1 phenotypic marker of natural killer cells produced by co-culturing the gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 5g is a diagram showing the expression level of the CXCR3 phenotype markers of natural killer cells prepared by co-culturing a gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- FIG. 6A is a diagram showing the activity (CD16 + CD56 +) of natural killer cells produced by co-culturing a gene-introduced H9 cell line and umbilical cord blood-derived CD3 (-) mononuclear cells for each introduced gene.
- FIG. 6B is a diagram showing the expression level of the NKG2D phenotype marker of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord-derived CD3 (-) monocytes by gene.
- 6c is a diagram showing the expression level of the NKp30 phenotype marker of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- 6D is a diagram showing the expression level of the NKp44 phenotype marker of natural killer cells produced by co-culturing the gene-introduced H9 cell line and umbilical cord blood-derived CD3 (-) monocytes for each gene.
- 6E is a diagram showing the expression level of the NKp46 phenotype marker of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- 6F is a diagram showing the expression level of the DNAM-1 phenotype marker of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord-derived CD3 (-) mononuclear cells for each introduced gene.
- Figure 6g is a diagram showing the expression level of the CXCR3 phenotype markers of natural killer cells prepared by co-culturing the gene-introduced H9 cell line and umbilical cord blood-derived CD3 (-) monocytes by gene.
- Figure 7a shows the activity (CD16 + CD56 +) and NKG2D phenotype of natural killer cells prepared by re-stimulation at intervals of 14 or 16 days when co-cultured with CD3 (-) monocytes derived from umbilical cord and Hut78 cell line with triple gene introduction It is a figure showing the expression level of a marker.
- Figure 7b is a NKp30, NKp44, NKp46, DNAM-1 of natural killer cells prepared by re-stimulation at intervals of 14 or 16 days when co-cultured with CD3 (-) monocytes derived from umbilical cord blood and Hut78 cell line with triple gene introduction , It is a diagram showing the expression level of the CXCR3 phenotype marker.
- 8A is a diagram showing the tumor cell killing capacity of natural killer cells prepared by co-culturing a gene-introduced Hut78 cell line and umbilical cord-derived CD3 (-) mononuclear cells by gene.
- 8B is a diagram showing the tumor cell killing ability of natural killer cells prepared by co-culturing a gene-introduced H9 cell line and umbilical cord-derived CD3 (-) monocytes by gene.
- Figure 8c is a diagram showing the tumor cell killing ability of the natural killer cells prepared by co-culturing the gene-introduced Jurkat cell line and umbilical cord-derived CD3 (-) monocytes by gene.
- Figure 8d is a diagram showing the tumor cell killing ability of natural killer cells prepared by co-culturing a gene-introduced Peer cell line and umbilical cord-derived CD3 (-) monocytes by gene.
- Figure 8e is a diagram showing the tumor cell killing ability of natural killer cells prepared by re-stimulation at intervals of 14 or 16 days when co-cultured with CD3 (-) monocytes derived from umbilical cord blood and the Hut78 cell line with the triple gene introduced.
- 9A is a diagram showing a dosing schedule for efficacy evaluation using a Raji mouse animal model.
- Figure 9b is a diagram showing the results of measuring the survival rate to confirm the efficacy of NK cells, RTX and combination administration in the Raji animal model.
- 10A is a diagram showing a dosing schedule for efficacy evaluation using a Ramos mouse animal model.
- Figure 10b is a diagram showing the results of measuring the survival rate to confirm the efficacy of NK cells, RTX and combination administration in a Ramos animal model.
- One aspect of the present invention provides a method for culturing natural killer cells comprising the step of co-culturing the transformed CD4 + T cells and the source cells.
- the transformed CD4 + T cells may be expressed by at least one gene selected from the group consisting of 4-1BBL gene, mbIL-21 gene, OX40L gene and mTNF- ⁇ gene.
- the gene when a single gene is introduced into the transformed CD4 + T cell, the gene may be 4-1BBL, mbIL-21, OX40L or mTNF- ⁇ .
- the gene combination when two genes are introduced into the transformed CD4 + T cells, the gene combination is mbIL-21 / 4-1BBL, 4-1BBL / OX40L, mTNF- ⁇ / 4-1BBL, mbIL-21 / OX40L, mbIL-21 / mTNF- ⁇ or mTNF- ⁇ / OX40L.
- genes of mbIL-21 / 4-1BBL, mTNF- ⁇ / OX40L, mTNF- ⁇ / 4-1BBL and mbIL-21 / OX40L combinations were introduced into T cells.
- the gene combination is 4-1BBL / mbIL-21 / OX40L, mbIL-21 / OX40L / mTNF- ⁇ , mTNF- ⁇ / mbIL-21 / It may be 4-1BBL or 4-1BBL / OX40L / mTNF- ⁇ .
- the gene of mTNF- ⁇ / mbIL-21 / 4-4BBL combination was introduced into T cells.
- the gene combination may be mTNF- ⁇ / mbIL-21 / OX40L / 4-1BBL.
- a gene of mTNF- ⁇ / mbIL-21 / OX40L / 4-1BBL combination was introduced into T cells.
- '4-1BBL' used in the present invention is one of TNFSF (TNFSF) called CD137L, and refers to a ligand that forms a trimer and binds to the receptor 4-1BB.
- TNFSF TNFSF
- the 4-1BBL gene may be derived from humans.
- the 4-1BBL gene may be NCBI Reference Sequence: NM_003811, but is not limited thereto.
- the 4-1BBL gene may be a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 1.
- the base sequence encoding the amino acid sequence represented by SEQ ID NO: 1 may be a base sequence represented by SEQ ID NO: 2.
- mbIL-21' used in the present invention may be IL-21 designed to bind to a cell membrane.
- mbIL-21 may be a fusion protein in which IL-21 and a transmembrane protein are combined.
- the transmembrane protein may be CD8 ⁇ . Specifically, it may be a transmembrane domain of CD8 ⁇ .
- the IL-21 gene may be NCBI Reference Sequence: NM_021803.3, but is not limited thereto.
- the CD8 ⁇ gene may be NCBI Reference Sequence: NM_001768, but is not limited thereto.
- the mbIL-21 is expressed in the form of IL-21 bound to the cell membrane.
- the mbIL-21 gene may be a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 3.
- the amino acid sequence represented by SEQ ID NO: 3 may be a nucleotide sequence represented by SEQ ID NO: 4.
- the term 'OX40L' used in the present invention is also called TNFSF4, gp34, TXGP1, CD252 and CD134L, and refers to a ligand that binds to OX40.
- the OX40L gene may be NCBI Reference Sequence: NM_003326, but is not limited thereto.
- the OX40L gene may be a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 5.
- the nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 5 may be a nucleotide sequence represented by SEQ ID NO: 6.
- 'mTNF- ⁇ ' used in the present invention refers to alanine-Valine, a recognition site for tumor necrosis factor-alpha-converting enzyme (TACE) in the amino acid sequence of tumor necrosis factor-alpha.
- TACE tumor necrosis factor-alpha-converting enzyme
- the mTNF- ⁇ gene may be a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 8.
- the nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 8 may be a nucleotide sequence represented by SEQ ID NO: 9.
- the 4-1BBL gene, mbIL-21 gene, OX40L gene or mTNF- ⁇ gene may be introduced through a recombinant lentivirus, but is not limited thereto.
- a biochemical method As a method for transducing the gene into cells, a biochemical method, a physical method, or a virus-mediated transduction method may be used.
- FuGene6 Roche, USA
- Lipofectamine 2000, Invitrogen, USA
- ExGen 500 MBI Fermentas International Inc. CANADA
- a lipid mediating method using lipofectamine can be used.
- vector used in the present invention is an expression vector capable of expressing a target gene in a cell into which the vector is introduced, a gene construct comprising essential regulatory elements operably linked to express a gene insert introduced into the vector.
- the expression vector containing the gene can be used any expression vector that can be expressed in the CD4 + cell line, in a specific embodiment of the present invention pCDH-CMV-MCS-EF1-Puro (SBI, CD510B-1) or pCDH -CMV-MCS-EF1-Neo (SBI, CD514B-1) lenti virus vector was used.
- the lentivirus refers to a virus of the retroviral family characterized by a long incubation period. Lenti virus can transmit genetic information into the DNA of the host cell. It is one of the most effective methods of gene transfer vectors that can replicate in non-dividing cells.
- the CD4 + T cells may be CD4 + T cells isolated in vitro, CD4 + T cells expanded in vitro or a CD4 + cell line (T lymphoma cell line).
- the CD4 + T cells may be auxiliary T cells, or may be hybridomas obtained by fusion of CD4 + T cells and cancer cells.
- CD4 + T cells may be any one selected from the group consisting of Hut78, H9, Jurkat, Loucy, Molt-3, Molt-13, Peer, RPMI8402 and TALL-01 cells. Preferably it can be Hut78, H9, Jurkat or Peer cells.
- the term 'feeder cell' used in the present invention is also referred to as a culture auxiliary cell, and does not proliferate, but has metabolic activity and means a cell that produces various metabolites and helps proliferation of target cells.
- the support cell may be a transformed CD4 + T cell expressing at least one gene selected from the group consisting of 4-1BBL gene, mbIL-21 gene, OX40L gene and mTNF- ⁇ gene.
- the T cell used as the support cell may be an inactivated cell or an inactivated cell in which mitosis is suppressed, and preferably, safety may be secured by inactivating.
- a conventional method known in the art may be used, and for example, a method of irradiating gamma-rays may be used.
- T cells that are not inactivated are used, they are mostly tumor cells, so they can be killed in culture by activated natural killer cells.
- seed cell used in the present invention means a cell that can proliferate into natural killer cells through appropriate culture.
- the source cells may be cord blood-derived mononuclear cells, or cord blood-derived natural killer cells. It is not limited thereto, and preferably, the source cells may be CD3 (-) cells from which CD3 (+) cells have been removed.
- the method for culturing the natural killer cells may be cultured by mixing the ratio of the supporting cells and the source cells to 0.1 or more.
- the ratio of the supporting cells and the source cells may be 0.1: 1 to 50: 1. More specifically, it may be 0.5: 1 to 40: 1. More specifically, it may be 1: 1 to 30: 1. Most specifically, it may be 2: 1 to 20: 1.
- the ratio of the supporting cells to the source cells may be a ratio of 2.5: 1, and is not particularly limited.
- the "ratio" means a ratio based on the number of cells.
- the source cells can be cultured for 5 to 60 days by mixing once with the support cells, or by mixing with the support cells two or more times for more than 60 days.
- the source cells can be cultured for 14 to 21 days by mixing once with the support cells, but are not limited thereto.
- the natural killer cell culture method is co-cultured with natural killer cells and T lymphoma cell lines in common animal cell culture media such as AIM-V media, RPMI1640, CellGro SCGM, X-VIVO20, IMDM, and DMEM.
- common animal cell culture media such as AIM-V media, RPMI1640, CellGro SCGM, X-VIVO20, IMDM, and DMEM.
- T cells have low affinity and can be cultured by adding antibodies and interleukins that stimulate T cells, but are not limited thereto.
- the term 'antibody having low affinity to T cells and stimulating T cells' used in the present invention specifically refers to CD3 antigen, a group of molecules that form an antigen recognition complex in association with T cell receptors (TCR). It means the protein to react.
- CD3 molecule has a longer intracellular region than TCR and is responsible for delivering an antigen recognition signal into the cell.
- Antibodies that have low affinity to T cells that can be used in the present invention and stimulate T cells may be preferably anti-CD3 antibodies.
- the anti-CD3 antibody may be OKT-3, UCHT1 or HIT3a.
- IL Interleukin
- IL-2 IL-15
- IL-12 IL-18
- IL-21 IL-21
- OKT-3 antibody and IL-2 were added to culture.
- the concentration of the OKT-3 antibody added may be 0.1 ng / ml to 1,000 ng / ml.
- the concentration of the OKT-3 antibody may be 10 ng / ⁇ l.
- the concentration of IL-2 can be from 10 U / ml to 2,000 U / ml.
- the concentration of IL-2 may be 1,000 U / ml.
- it can be cultured by adding an additional proliferation factor supporting the growth of serum or plasma and lymphocytes.
- the type of serum or plasma added to the medium is not particularly limited, and various commercially available animal-derived serum or plasma can be used.
- human-derived serum or plasma can be used.
- culture of the present invention means a method for growing cells under environmental conditions that are artificially controlled appropriately.
- the method of culturing the transformed CD4 + T cells can be performed using methods well known in the art. Specifically, the culture may be continuously cultured in a batch process, a fed batch, or a repeated fed batch process.
- precursors suitable for the culture medium may be used.
- the above-mentioned raw materials may be added in a batchwise, fed-batch, or continuous manner in an appropriate manner to the culture in the culture process, but are not particularly limited thereto.
- the pH of the culture can be adjusted by using a basic compound such as sodium hydroxide, potassium hydroxide or ammonia or an acid compound such as phosphoric acid or sulfuric acid in an appropriate manner.
- the culture method using the T cell as a support cell induces the cultivation of natural killer cells selectively from the source cells, and stably without the difference according to the donor when proliferating the natural killer cells than when using the donor PBMC support cells. Can be cultured. Also, when the donor's MNC is used as a support cell, it is difficult to culture the umbilical cord blood source cells in vitro. Therefore, the culture method using T cells as support cells can efficiently and stably secure a therapeutic agent for natural killer cells for a large amount of treatment.
- Another aspect of the present invention provides a natural killer cell prepared by the natural killer cell culture method.
- the natural killer cells cultured according to the natural killer cell culturing method can be frozen and the function of the cells is not impaired even when thawed again.
- an activating receptor such as NKp46
- the killing ability and cytokine secretion to the tumor cell line are increased, and thus an excellent anticancer effect can be expected. Therefore, it is possible to manufacture a cell therapy agent effective for tumor treatment using a large amount of activated natural killer cells that can be clinically applied.
- composition for preventing or treating infectious diseases comprising natural killer cells prepared by the natural killer cell culture method as an active ingredient.
- the composition for preventing or treating an infectious disease of the present invention may further include one or more active ingredients having the same or similar function in addition to the active ingredients.
- the pharmaceutical composition for preventing or treating infectious diseases may be formulated into a pharmaceutical composition including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
- the dosage of the pharmaceutical composition for the prevention or treatment of infectious diseases is the type of disease, the severity of the disease, the type and content of active ingredients and other ingredients contained in the composition, the type of formulation and the patient's age, weight, and general health status , Gender and diet, time of administration, route of administration and composition, secretion rate, duration of treatment, and drugs to be used simultaneously.
- the dose of NK cells according to the invention 0.01x10 7 cells / kg to may be 1.0x10 9 cells / kg, be 0.5x10 7 cells / kg to 1.0x10 8 cells / kg have.
- the administration may be administered once a day, or may be divided into multiple administrations.
- the pharmaceutical composition for preventing or treating the infectious disease may be administered to an individual by various methods known in the art.
- the administration route may be appropriately selected by a person skilled in the art in consideration of the administration method, the volume of body fluids, viscosity, and the like.
- Another aspect of the present invention provides a composition for culturing natural killer cells comprising transformed CD4 + T cells as an active ingredient. Since CD4 + T cells used in the present invention and genes introduced into the cells have already been described above, the description thereof is omitted to avoid excessive duplication.
- Example 1.1 Recombinant lentivirus vector production
- pCDH-CMV-MCS-EF1-Puro SBI, CD510B-1
- pCDH-CMV-MCS-EF1-Neo SBI, CD514B-1
- Genes introduced 4-1BBL TNF superfamily member 9, TNFSF9
- mbIL-21 membrane bound IL-21
- OX40L TNF superfamily member 4 (TNFSF4) transcript variant 1
- mTNF- ⁇ membrane bound TNF alpha
- 4-1BBL gene a 4-1BBL gene expression vector (Origene, RC211160) was used.
- mbIL-21 gene SEQ ID NO: 4
- a pcDNA3.1 vector Genscript, US
- OX40L gene SEQ ID NO: 6
- the mTNF- ⁇ gene (SEQ ID NO: 9) extracted RNA from peripheral blood mononuclear cells (PBMC), and then CDS was obtained by RT (Reverse transcriptase) -PCR. In order for TNF- ⁇ to be secreted, it is cut by TACE (tumor necrosis factor-alpha-converting enzyme). DNA in the TNF- ⁇ amino acid sequence turns the TACE recognition site AV (Alanine-Valine) into PV (Proline-Valine) In the phase, a point mutation was caused to maintain the state attached to the cell membrane. The point mutation is performed by replacing 226th base guanine with cytosine and 228th base adenine with guanine in the human mTNF- ⁇ gene represented by SEQ ID NO: 7. Did.
- CDS Coding Sequence
- Table 1 above shows the primers used in the experiment.
- the introduced gene and lentiviral vector were treated with EcoRI and BamHI restriction enzymes. Then, it was ligated using an In-Fusion HD cloning kit (Clontech, 639649). The ligated lentiviral vector was transformed into DH5 ⁇ soluble cells and cultured. Plasmid DNA was obtained from the transformed DH5 ⁇ soluble cells using a plasmid mini-prep kit (MACHEREY-NAGEL / 740422.50). All plasmid DNAs were subjected to sequencing by an external company to confirm that the DNA sequences matched.
- cLV-CMV-MCS-IRES-Puro puromycin
- cLV-CMV-MCS-IRES-Neo was confirmed by a subcontractor. (neomycin), cLV-CMV-MCS-IRES-Bsd (blasticidin) was inserted with the desired introduction gene in the same manner as above.
- 293T cell lines were inoculated into 75T flasks (Nunc, 156499) with 1.5x10 6 to 2x10 6 cells 2 days before transfection and cultured in an incubator at a temperature of 5% CO 2 and 37 ° C.
- the medium was replaced with 6 mL OPTI-MEM (Gibco, 31985-088) and incubated for 30 minutes at 37 ° C under 5% CO 2 conditions.
- a DNA mixture and a lipofectamine (lipofectamine 2000, Life technologies, 11668500) mixture were prepared (Table 2).
- Table 2 shows the DNA mixture and lipofectamine (lipofectamine 2000, Life technologies, 11668500) mixture.
- the components of each mixture were well mixed using a vortexer and left at room temperature for 3 minutes. Thereafter, the two mixtures were mixed and left at room temperature for 20 minutes or more.
- 2 ml of the solution in which DNA and lipofectamine were mixed were treated with 293T cells cultured in 6 ml OPTI-MEM medium. After 4 hours, the medium was replaced with DMEM (Gibco, 11995073) medium to which 10% (v / v) FBS was added, and incubated with 5% CO 2 at 37 ° C. for 48 hours.
- DMEM Gibco, 11995073
- 0.5x10 6 in culture Cell line and 1 ml OPTI-MEM medium, 50 ⁇ l lentiviral thaw solution, 10 ⁇ g / ml polybrene (polybrene, Santa Cruz, C2013) were mixed and placed in a 6-well plate (6-well plate, Nunc, 140675) and 1800 Spinoculation was performed for 90 minutes at a temperature of ⁇ g and 32 ° C. Then, after incubating in an incubator at a temperature condition of 5% CO 2 and 37 ° C. for 2 hours, it was replaced with an existing culture medium and cultured for 48 hours.
- the Hut78 cell line (ATCC, TIB-161 TM) was cultured in IMDM (ATCC, 30-2005) medium containing 20% (v / v) FBS. When subcultured cell concentration was kept at 1.5x10 5 cells / ml to 2.0x10 5 cells / ml.
- H9 cell line (ATCC, HTB-176 TM) and Jurkat cell line (ATCC, TIB-152 TM) were cultured in RPMI1640 (ATCC, 30-2001) medium containing 10% (v / v) FBS.
- Table 3 shows antibiotics used in the cell line into which the gene has been introduced.
- Example 2.1 To confirm the expression of the introduced gene through flow cytometry, the cell lines passaged in Example 2.1. Were collected and centrifuged at 1,200 rpm for 5 minutes. Then, the culture solution was removed by suction. FACS buffer was prepared by adding 2% (v / v) FBS to PBS. Cell number was measured by diluting with 1 ml of FACS buffer and diluted with FACS buffer to a concentration of 5x10 6 cells / ml. 100 ⁇ l of the diluted cell solution was added to a 5 ml FACS tube (Falcon, 352052).
- Anti-human TNF-a (membrane) -PE R & D systems, FAB210P
- anti-human OX40L-PE BD, 558184
- anti-human 4-1BBL-PE BD, 559446
- anti-human IL-21 -PE eBioscience, 12-7219-42
- 7-AAD Beckman coulter, IM3630c
- PE mouse IgG1 ⁇ isotype control BD Pharmingen, 555749
- PerCP-Cy5.5 mouse IgG1 ⁇ isotype control BD, 550795)
- RT-qPCR Real time qPCR
- the cell lines passaged in Example 2.1 Were collected and centrifuged at 1,200 rpm for 5 minutes. Then, the culture solution was removed by suction. Cell number was measured by dilution with PBS, and 1x10 6 cells were separated and quantified using an RNA prep kit.
- cDNA was synthesized using the cDNA synthesis kit.
- RT-qPCR was performed using the synthesized cDNA. Primers used for RT-qPCR are shown in Table 4 below.
- Table 4 above shows the primers used in the RT-qPCR experiment.
- the expression level of the gene introduced into the cell line is shown in Table 5 below.
- the research cord blood was placed in a 50 ml tube and centrifuged for 10 minutes at 1,500 rpm.
- the upper plasma was removed and PBS (phosphate buffered saline, LONZA, 17-516Q) was added in a 1: 1 ratio.
- PBS phosphate buffered saline
- the umbilical cord blood mononuclear cells were separated through a ficoll density gradient centrifugation method (Ficoll-Paque Plus, GE Healthcare, 17-1440-03), followed by an ADAM cell counter system. (ADAM cell counter system, Nano Entec) was used to measure the number of cells.
- Cells were separated by mounting a CS column (column, Miltenyi Biotech, 130-041-305) to VarioMACS (Miltenyi Biotech). The cells were recovered by washing the column until the final 20 ml. The collected cells were placed in a new 50 ml tube, centrifuged for 5 minutes at 1,200 rpm and 4 ° C, and suspended in a frozen medium. The number of cells was measured using an ADAM cell counter system to freeze 5x10 6 cells per vial in liquid nitrogen.
- CD3 (-) umbilical cord blood mononuclear cells 1 was thawed in a 37 ° C water bath and transferred to a 50 ml tube, 0.6% (v / v) ACD (Citrate-dextrose solution, Sigma-Aldrich, C3821) ), 0.2% (v / v) suspended in PBS containing FBS (Fetal serum bovine) and 2 mM EDTA, and centrifuged at 1,500 rpm and 4 ° C for 10 minutes.
- CD3 (-) cord blood mononuclear cells were suspended in CellGro medium (Cellgenix, 20802-0500), and the cell number was measured using an ADAM cell counter system.
- CD3 (-) cord blood mononuclear cells were suspended in CellGro medium to a concentration of 1x10 6 cells / ml.
- Example 3.2 Co-culture of CD3 (-) cord blood mononuclear cells and transgenic T cells
- the transgenic T cells prepared in Example 2 were recovered from the culture flask and centrifuged at 1,200 rpm and 4 ° C for 5 minutes. Thereafter, it was suspended in CellGro medium and the cell number was measured using an ADAM cell counter system. The transgenic T cells were suspended in CellGro medium at a concentration of 2.5x10 6 cells / ml, and then irradiated with 20,000 cGy in a gamma-ray irradiator to prepare them.
- IL-2 Proleukin, Novartis Korea
- OKT-3 eBioscience, 16-0037-85
- CD3 (-) umbilical cord blood mononuclear cells and transgenic T cells were added at a ratio of 1: 2.5 at 0.25 ml each, and 0.25 ml of CellGro medium containing 2% (v / v) human plasma was added, followed by an incubator at a temperature of 37 ° C. Incubation was continued for 4 days.
- CellGro medium containing 1% (v / v) human plasma and 1,000 IU / mL of IL-2 was added in the same amount, followed by static culture. Thereafter, the cell number was measured at intervals of 2 to 3 days to add 1% (v / v) human plasma, and CellGro medium containing 1,000 IU / mL of IL-2 to a concentration of 1x10 6 cells / mL. It was suspended and cultured. Suspended culture was performed until day 21 to obtain proliferated natural killer cells. At this time, when the Jurkat cell line or Peer cell line was used as a support cell, the cells were suspended and cultured until 11 days. When the gene was introduced into the H9 and Hut78 cell lines and used as support cells, the cells were suspended and cultured until 21 days.
- CD3 (-) cells isolated from umbilical cord blood mononuclear cells are cultured for 21 days with support cells into which genes have been introduced, and that natural killer cells can be cultured, and have higher proliferation rates than non-gene-supported support cells.
- Example 3.3 Re-stimulation of natural killer cell culture using HuT78 cells introduced with mTNF- ⁇ / mbIL-21 / 4-1BBL gene
- the transgenic T cells prepared in Example 2 were recovered from the culture flask and centrifuged at 1,200 rpm and 4 ° C for 5 minutes. Thereafter, it was suspended in CellGro medium and the cell number was measured using an ADAM cell counter system. The transgenic T cells were suspended in CellGro medium at a concentration of 2.5x10 6 cells / ml, and then irradiated with 20,000 cGy in a gamma-ray irradiator to prepare them.
- CellGro medium containing 1% (v / v) human plasma and 1,000 IU / mL of IL-2 was added in the same amount, followed by static culture. Subsequently, the cell number was measured at intervals of 2 to 3 days, and cultured by adding CellGro medium containing 1% (v / v) human plasma and 1,000 IU / mL of IL-2 to a concentration of 1x10 6 cells / mL.
- HuT78 cells into which mTNF- ⁇ / mbIL-21 / 4-1BBL gene was introduced on day 0 of culture were used at the same rate. On the 16th day of culture, the first re-stimulation was given. First, the number of natural killer cells in culture was measured using an ADAM cell counter system, diluted with CellGro medium to be 1.5x10 6 cells / ml, and 0.25 ml was prepared in a culture plastic plate.
- HuT78 cells into which mTNF- ⁇ / mbIL-21 / 4-1BBL gene was introduced were suspended in CellGro medium to be 2.5x10 6 cells / ml, and then irradiated with 10,000 cGy in a gamma-ray irradiator to prepare.
- HuT78 cells into which the inactivated mTNF- ⁇ / mbIL-21 / 4-1BBL gene was introduced were placed in a culture plate of 0.25 ml. 1000 IU / mL of IL-2 and 10 ng / mL of OKT-3, 1% (v / v) human plasma were placed in a culture plastic plate and cultured for 3 days in an incubator at a temperature of 37 ° C. Thereafter, the cell number was measured at intervals of 2 to 3 days, and cultured by adding CellGro medium containing 1% (v / v) human plasma and 1000 IU / mL IL-2 to 1x10 6 cells / mL. After the first re-stimulation, re-stimulation through support cells was performed on the 32nd, 46th, and 60th days of culture in the same manner every 14 days, and the culture was continued until 70th.
- the proliferation rate of natural killer cells on the 32nd day after the first restimulation was 6.9x10 4 times
- the second restimulation was 3.7x10 6 times
- the culture was 2.3x10 8 times, the fourth time.
- continuous proliferation was maintained at 5.9x10 9 fold on the 70th day of culture to show a high proliferation rate (Table 10, FIG. 2e).
- an ADAM cell counter system one of the cell counters using a PI staining solution capable of binding to the intracellular nucleus, was used. After subtracting the number of dead cells from the measured total cell number, the number of viable cells was calculated, and then cell viability was calculated using Equation I below.
- the survival rate of natural killer cells cultured in the cell line introduced with the mbIL-21 / 4-1BBL gene and the cell line introduced with the mTNF- ⁇ / mbIL-21 / 4-1BBL gene is 21. Survival rate of 90% or more was observed in day culture (H9) and 11 day culture (Jurkat, Peer) (Table 12 to Table 14, FIGS. 3B to 3D).
- Natural killer cells cultured on the 21st or natural killer cells cultured by repeated re-stimulation were collected, centrifuged at 1,200 rpm for 5 minutes, and the culture solution was aspirated and removed. Cell number was measured by diluting with 1 mL of FACS buffer, and diluted with FACS buffer to 5x10 6 cells / mL. 100 ⁇ l of the diluted cell solution was added to a 5 ml FACS tube (Falcon, 352052), and the phenotype was analyzed with the following antibody:
- Tube 1 anti-human CD3-FITC (BD Pharmingen, 555332), anti-human CD16-PE (BD Pharmingen, 555407), anti-human CD56-BV421 (BD Pharmingen, 562751)
- Tube 2 anti-human CD14-FITC (BD Pharmingen, 555397), anti-human CD19-PE (BD Pharmingen, 555413), anti-human CD3-BV421 (BD Pharmingen, 562438)
- Tube 3 anti-human CD3-FITC, anti-human NKG2D-PE (R & D system, FAB139P), anti-human CD56-BV421
- Tube 4 anti-human CD3-FITC, anti-human NKp30-PE (BD Pharmingen, 558407), anti-human CD56-BV421
- Tube 5 anti-human CD3-FITC, anti-human NKp44-PE (BD Pharmingen, 558563), anti-human CD56-BV421
- Tube 6 anti-human CD3-FITC, anti-human NKp46-PE (BD Pharmingen, 557991), anti-human CD56-BV421
- Tube 7 anti-human CD3-FITC, anti-human DNAM-1-PE (BD Pharmingen, 559789), anti-human CD56-BV421
- Tube 8 anti-human CD3-FITC, anti-human CXCR3-PE (BD Pharmingen, 557185), anti-human CD56-BV421
- Tube 9 anti-human CD3-FITC, PE mouse IgG1 ⁇ isotype control (BD Pharmingen, 555749), anti-human CD56-BV421
- Tube 10 FITC mouse IgG1 ⁇ isotype control (BD Pharmingen, 555748), PE mouse IgG1 ⁇ isotype control, BV421 mouse IgG1 ⁇ isotype control (BD Pharmingen, 562438)
- the anti-human CD56 in the tube 1 was performed by selecting one of three fluorescences, and accordingly, the fluorescence of the CD3 of tube 2, the CD56 of tubes 3 to 9, and the isotype control of tube 10 was performed. I chose the same thing.
- the tubes were dyed at refrigeration temperature for 30 minutes. Thereafter, 2 ml FACS buffer was added to the stained cells, and centrifugation was performed at 1,500 rpm for 3 minutes. The supernatant was removed, 2 ml of FACS buffer was added again, and centrifugation was performed at 2,000 rpm for 3 minutes. After removing the supernatant again, 200 ⁇ l cytofix buffer (fixation buffer, BD, 554655) was added and suspended, and the cell was identified and purified using FACS LSRII Fortessa (BD Biosciences) and various phenotypes.
- FACS LSRII Fortessa BD Biosciences
- mTNF- ⁇ / mbIL-21 / 4-1BBL is a cell line in which three genes are introduced, and natural killer cells cultured by increasing the number of re-stimulation have a high content of natural killer cells (CD3-CD56 +) of 90% or more until 60 days of culture. It was confirmed (Table 20, Figure 4e)
- CD16 When co-cultured with the HuT78 cell line, CD16 was highly expressed, and the dual marker transduction support cells were compared to the conditions in which the active markers NKG2D, NKp30, NKp44, NKp46, and DNAM-1 did not introduce genes or single transduction support cell conditions. In the conditions, all were highly expressed without variation between donors (FIGS. 5A to 5G).
- mTNF- ⁇ / mbIL-21 / 4-1BBL was confirmed by co-culturing the natural killer cell phenotype by re-stimulation using Hut78 cell line in which three genes were introduced.
- the expression of active markers such as NKG2D, NKp44, NKp46, DNAM-1, and CXCR3 tended to decrease. Through this, it was confirmed that as the number of times of re-stimulation increased, the expression period of some active markers could be influenced as the incubation period became longer (FIGS. 7A and 7B).
- the tumor cell line was washed with 10 ml to 15 ml of RPMI1640 medium containing 10% (v / v) FBS, centrifuged, and the pellet was added to 10 ml of 10% (v / v) FBS. It was suspended in the added RPMI1640 medium to make a concentration of 1x10 5 cells / ml.
- Natural killer cells were centrifuged by placing 1x10 6 cells in a 15 ml tube, and the pellet was suspended in RPMI1640 medium to which 10% (v / v) FBS was added at a desired ratio (1: 1) compared to the K562 cancer cell line.
- the prepared K562 cancer cell line and natural killer cell line were mixed and dispensed in 100 ⁇ l in a round-bottom 96-well U-bottom plate (Nunc, 163320), and each well was prepared in triplicates to obtain an average value.
- the plate After blocking the light to react for 4 hours in an incubator at a temperature of 37 ° C., the plate was centrifuged at 2,000 rpm for 3 minutes. The supernatant was dispensed at 100 ⁇ l in a 96-well black plate (96 well black plate, Nunc, 237108). The fluorescence value (OD 480/535 nm) was measured using a fluorescence plate reader (Perkin Elmer, VICTOR X3), and the tumor cell killing capacity of natural killer cells was calculated using Equation II below.
- % of killing (Sample well average fluorescence value-Spon well average fluorescence value) / ⁇ (Max well average fluorescence value + A)-Spon well average fluorescence value ⁇ x 100
- Direct killing ability was measured by reacting natural killer cells cultured with various support cells with the K562 cancer cell line.
- the cell killing ability of natural killer cells cultured under the condition of introducing the mbIL-21 / 4-1BBL gene and mTNF- ⁇ / mbIL-21 / 4-1BBL gene was higher than that of the condition in which no gene was introduced for all support cells. Increased (FIGS. 8A to 8D).
- the cell killing ability of natural killer cells according to the number of re-stimulation of HuT78 cell line into which mTNF- ⁇ / mbIL-21 / 4-1BBL gene was introduced showed high killing ability up to 60 days in culture without significant difference (FIG. 8E).
- Example 4.1 Culture of natural killer cells using transgenic T support cells
- the transgenic T support cells were re-stimulated at a ratio of 1: 2.5 and cultured in CellGro medium containing 1 V / V% human plasma and OKT3, IL-2. Thereafter, the cell number was measured at intervals of 2-3 days to add 1 V / V% human plasma and CellGro medium containing 1000 IU / mL of IL-2 to 1 x 10 6 cells / mL, and further cultured for 14 days. The cells were cultured for a total of 28 days.
- the culture of natural killer cells derived from peripheral blood was as follows: On the 4th day of culture, the same amount of CellGro medium containing 1 V / V% human plasma and 500 IU / mL of IL-2 was added, followed by static culture. Thereafter, cell counts were measured at intervals of 2 to 3 days to add 1 V / V% human plasma and 500 IU / mL of IL-2 CellGro medium to 1 x 10 6 cells / mL, and cultured until 11 days. . On day 11 of culture, the transgenic T support cells were re-stimulated at a ratio of 1: 2.5 and cultured in CellGro medium containing 1 V / V% human plasma and OKT3, IL-2.
- the cell number was measured at intervals of 2 to 3 days to add 1 V / V% human plasma and 1000 IU / mL of IL-2 CellGro medium to 1 x 10 6 cells / mL.
- the cells were further cultured to culture the cells for a total of 19 to 21 days.
- the cultured cells are suspended in a freezing medium to be 1 x 10 6 cells / mL, frozen using a temperature-controlled cell freezer and stored in liquid nitrogen.
- the Raji-luci cell line was collected on the last day of culture, and the cell concentration was adjusted to 5 x 10 5 cells / mL using PBS, and then injected into the tail vein at a rate of 0.2 mL (1 x 10 5 cells / mouse) per mouse.
- Natural killer cells were injected into the tail vein at 2 x 10 7 cells / 200 ⁇ L, and rituxan (hereinafter RTX, Mab Terraju, Roche, Korea) was diluted with PBS to a concentration of 0.01 ⁇ g / 100 ⁇ L to weaken the area between the mouse shoulder and chest wall. Injected subcutaneously 100 ⁇ L.
- the NK cells were administered to the tail vein a total of 6 times using the immobilizer the next day after cancer cell transplantation, and RTX was administered subcutaneously once (Table 22, FIG. 9A).
- Ramos cell line was collected cancer cells on the last day of culture, the cell concentration was adjusted to 5 x 10 6 cells / mL using PBS, and 0.2 mL (1 x 10 6 cells / mouse) per mouse was injected into the tail vein.
- Natural killer cells were injected into the tail vein at 2 x 10 7 cells / 200 ⁇ L, and RTX was diluted with PBS to a concentration of 0.3 ⁇ g / 100 ⁇ L and injected 100 ⁇ L subcutaneously at the weakened area between the mouse shoulder and chest wall. Natural killer cells were administered to the tail vein a total of 6 times from the fourth day of cancer cell transplantation, and RTX was administered to the ring vein 6 times from the third day of cancer cell transplantation (Table 24, FIG. 10A).
Abstract
Description
유전자 | 프라이머 | 서열정보 (5'->3') | 서열번호 |
4-1BBL | 4-1BBL Forward | TCTAGAGCTAGCGAATTCGCCACCATGGAATACGCCTCTGACGCTT | 서열번호 10 |
4-1BBL Reverse | TTCGCGGCCGCGGATCCTTATTCCGACCTCGGTGAAGG | 서열번호 11 | |
mbIL-21 | mbIL-21 Forward | TAGAGCTAGCGAATTCGCCACCGCCACCATGGCTCTGCCC | 서열번호 12 |
mbIL-21 Reverse | TCGCGGCCGCGGATCCTCAATACAGGGTGATGACC | 서열번호 13 | |
OX40L | OX40L Forward | TAGAGCTAGCGAATTCGCCACCATGGAACGGGTGCAAC | 서열번호 14 |
OX40L Reverse | TCGCGGCCGCGGATCCTCACAAGACACAGAACTCCCC | 서열번호 15 | |
mTNF-α | mTNF-α Forward | TAGAGCTAGCGAATTCGCCACCGCCACCATGGCTCTGCCC | 서열번호 16 |
mTNF-α Reverse | TCGCGGCCGCGGATCCTCACAGGGCAATGATCCC | 서열번호 17 |
구 분 | 성 분 |
DNA 혼합액 | 6 ㎍ 타겟 DNA, 6 ㎍ Gag, 6 ㎍ REV, 3 ㎍ VSVG, 1 ㎖ OPTI-MEM |
리포펙타민 혼합액 | 36 ㎕ lipofectamine 2000, 1 ㎖ OPTI-MEM |
도입 유전자 조합 | 사용한 vector | 세포주 | 항생제 사용 농도 | |
단일 유전자 발현 | mTNF-ambIL-21 | pCDH(System Biosciences, SBI) | Hut78 | 0.5 ㎍/㎖ puromycin (Life technologies, A1113802) |
OX40L4-1BBL | pCDH(System Biosciences, SBI) | Hut78 | 1 ㎎/㎖ G148(Sigma Aldrich, A1720-5G) | |
이중 유전자 발현 | mTNF-a/OX40LmbIL-21/OX40LmTNF-a/4-1BBL | pCDH(System Biosciences, SBI) | Hut78 | 0.5 ㎍/㎖ puromycin1 ㎎/㎖ G418 |
mbIL-21/4-1BBL | cLV (Sirion) | Hut78H9JurkatPeer | 6 ㎍/㎖ Blasticidin(Invitrogen, R210-01)1 ㎎/㎖G418 | |
삼중 유전자 발현 | mTNF-a/mbIL-21/4-1BBL | cLV (Sirion) | Hut78H9Jurkat | 0.5 ㎍/㎖ puromycin6 ㎍/㎖ Blasticidin1 ㎎/㎖ G418 |
사중 유전자 발현 | mTNF-a/mbIL-21/OX40L/4-1BBL | mTNF-a/mbIL-21/4-1BBL: cLVOx40L: pCDH | Hut78 | 0.5 ㎍/㎖ puromycin6 ㎍/㎖ Blasticidin1 ㎎/㎖ G418 |
프라이머 | 서열정보 (5'->3') | 서열번호 | |
4.1BBL | Forward primer | TCTGAGACAGGGCATGTTTG | 서열번호 18 |
Reverse primer | CCACCAGTTCTTTGGTGTCC | 서열번호 19 | |
mTNF-α | Forward primer | AACCTCCTCTCTGCCATCAA | 서열번호 20 |
Reverse primer | ATAGTCGGGCCGATTGATCT | 서열번호 21 | |
mbIL-21 | Forward primer | TGGAAACAATGAGCGAATCA | 서열번호 22 |
Reverse primer | AACCGCTCCAGGAACTCTTT | 서열번호 23 | |
hTOP1 | Forward primer | CCAGACGGAAGCTCGGAAAC | 서열번호 24 |
Reverse primer | GTCCAGGAGGCTCTATCTTGAA | 서열번호 25 |
Ct value | TOP1 | mTNF-α | mbIL-21 | 4.1BBL |
H9 | 20.3 | 21.5 | n.d | n.d |
H9-mbIL-21-4.1BBL | 20.0 | 22.2 | 19.5 | 19.4 |
H9-mTNF-α-mbIL-21-4.1BBL | 19.9 | 18.2 | 18.1 | 18.2 |
Jurkat | 20.1 | 30.7 | n.d | n.d |
Jurkat-mbIL-21-4.1BBL | 27.4 | 37.0 | 36.4 | 34.1 |
Jurkat-mTNF-α-mbIL-21-4.1BBL | 20.4 | 19.8 | 19.2 | 19.8 |
Peer | 21.4 | 26.2 | 34.2 | 34.9 |
Peer-mbIL-21-4.1BBL | 26.8 | 33.8 | 29.0 | 25.6 |
* n.d: not detected |
HuT78 + 도입유전자 | Average | STDEV |
HuT78 parental | 92.7 | 90.4 |
mTNF-α | 112.3 | 67.2 |
mbIL-21 | 448.1 | 251.4 |
OX40L | 50.5 | 30.7 |
4.1BBL | 274.9 | 189.6 |
mTNF-α+OX40L | 204.5 | 123.2 |
mTNF-α+4.1BBL | 389.1 | 352.1 |
mbIL-21+OX40L | 372.0 | 189.2 |
mbIL-21+4.1BBL | 957.0 | 537.4 |
mTNF-α+mbIL21+4.1BBL | 1138.5 | 192.0 |
mTNF-α+OX40L+mbIL21+4.1BBL | 823.1 | 330.0 |
H9 + 도입유전자 | Average | STDEV |
H9 parental | 12.6 | 4.3 |
mbIL21+4.1BBL | 367.4 | 80.1 |
mTNF-α+mbIL21+4.1BBL | 978.8 | 287.7 |
Jurkat + 도입유전자 | Average (11일 배양) | STDEV |
Jurkat Parental | 0.9 | 0.7 |
mbIL21+4.1BBL | 36.3 | 4.8 |
mTNF-α+mbIL21+4.1BBL | 43.6 | 6.6 |
Peer + 도입유전자 | Average (11일 배양) | STDEV |
Peer Parental | 1.6 | 0.7 |
mbIL21+4.1BBL | 14.3 | 4.1 |
배양일차 | Average | STDEV |
32일 | 6.9x104 | 3.2x103 |
46일 | 3.7x106 | 3.1x105 |
60일 | 2.3x108 | 1.4x108 |
70일 | 5.9x109 | 1.1x108 |
HuT78 + 도입유전자 | Average | STDEV |
Parental | 91 | 2.6 |
mTNF-α | 92.8 | 2.1 |
mbIL-21 | 92.8 | 1.5 |
OX40L | 90.3 | 1.3 |
4.1BBL | 91.3 | 1.3 |
mTNF-α+OX40L | 93.5 | 1.7 |
mTNF-α+4.1BBL | 92.5 | 1.7 |
mbIL-21+OX40L | 89 | 2.4 |
mbIL-21+4.1BBL | 89.8 | 2.6 |
mTNF-α+mbIL-21+4.1BBL | 89 | 3.4 |
QD | 88.5 | 3.4 |
H9 +도입유전자 | Average | STDEV |
Parental | 86 | 6.1 |
mbIL21+4.1BBL | 91 | 3.1 |
mTNF-α+mbIL21+4.1BBL | 94 | 0.6 |
Jurkat +도입유전자 | Average | STDEV |
Parental | 80 | 6.1 |
mbIL21+4.1BBL | 91 | 0.6 |
mTNF-α+mbIL21+4.1BBL | 92 | 2.0 |
Peer +도입유전자 | Average | STDEV |
Parental | 83.5 | 6.1 |
mbIL21+4.1BBL | 91 | 0.6 |
배양일차 | 32일 | 42일 | 60일 | 70일 |
Average | 96.0 | 93.5 | 97.5 | 91.5 |
STDEV | 1.4 | 0.7 | 0.7 | 4.9 |
HuT78 + 도입유전자 | Average | STDEV |
Parental | 92.4 | 9.6 |
mTNF-α | 96.8 | 2.5 |
mbIL-21 | 98.6 | 0.9 |
OX40L | 95.7 | 3.6 |
4.1BBL | 98 | 1.8 |
mTNF-α+OX40L | 97.2 | 2.5 |
mTNF-α+4.1BBL | 98.6 | 1 |
mbIL-21+OX40L | 98.4 | 1.3 |
mbIL-21+4.1BBL | 98.5 | 0.9 |
mTNF-α+mbIL-21+4.1BBL | 98.7 | 0.9 |
QD | 99.3 | 0.5 |
H9 +도입유전자 | Average | STDEV |
Parental | 91.5 | 4.1 |
mbIL21+4.1BBL | 98.5 | 0.7 |
mTNF-α+mbIL21+4.1BBL | 99 | 0.3 |
Jurkat +도입유전자 | Average | STDEV |
Parental | 88.6 | 6.9 |
mbIL21+4.1BBL | 97.6 | 1.3 |
mTNF-α+mbIL21+4.1BBL | 97.5 | 0.8 |
Peer +도입유전자 | Average | STDEV |
Parental | 79.2 | 14.6 |
mbIL21+4.1BBL | 94.9 | 2.1 |
배양일차 | 32일차 | 60일차 |
Avergage | 99.7 | 97.8 |
STDEV | 0.1 | 0.8 |
평균 | STDEV | |
CB-enFeeder | 79288.3 | 37381.0 |
PBMC-enFeeder | 53649.3 | 16827.9 |
군 | 용량 | 투여경로 | 액량(μl) | 마리수 |
1 | 동결배지+IgG 0.01 μg /head | i.v+s.c | 200+100 | 10 |
2 | RTX 0.01 μg /head | s.c | 100 | 10 |
3 | PBMC-enFeeder NK 2x107cells/head | i.v | 200 | 10 |
4 | CB-eFeeder NK 2x107cells/head | i.v | 200 | 10 |
5 | PB-eFeeder NK +RTX | i.v+s.c | 200+100 | 10 |
6 | CB-eFeeder NK +RTX | i.v+s.c | 200+100 | 10 |
Raji-luci 모델 | 동결배지 | RTX | PBMC-enFeeder | CB-enFeeder | RTX +PBMC-enFeeder | RTX +CB-enFeeder |
평균생존율 | 29.5 | 48.5 | 43 | 47 | 55 | 75.5 |
군 | 용량 | 투여경로 | 액량(μl) | 마리수 |
1 | 동결배지+IgG 0.3 μg /head | i.v+i.v | 200+100 | 10 |
2 | RTX 0.3 μg /head | i.v | 100 | 10 |
3 | PBMC-enFeeder NK 2x107cells/head | i.v | 200 | 10 |
4 | CB-eFeeder NK 2x107cells/head | i.v | 200 | 10 |
5 | PB-eFeeder NK +RTX | i.v+i.v | 200+100 | 10 |
6 | CB-eFeeder NK +RTX | i.v+i.v | 200+100 | 10 |
Ramos 모델 | 동결배지 | RTX | PBMC-enFeeder | CB-enFeeder | RTX +PBMC-enFeeder | RTX + CB-enFeeder |
평균생존율 | 31 | 49.5 | 42 | 42.5 | 63.5 | 87.5 |
Claims (26)
- 형질전환된 CD4+ T세포와 원료세포를 공동배양하는 단계를 포함하는 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 형질전환된 CD4+ T세포는 4-1BBL 유전자, mbIL-21 유전자, OX40L 유전자 및 mTNF-α 유전자로 구성된 군으로부터 선택되는 적어도 하나의 유전자가 발현되는 것인, 자연살해세포 배양방법.
- 제 2항에 있어서, 상기 4-1BBL 유전자는 서열번호 1로 표시되는 아미노산 서열을 코딩하는 염기서열인 것인, 자연살해세포 배양방법.
- 제 3항에 있어서, 상기 서열번호 1로 표시되는 아미노산 서열을 코딩하는 염기서열은 서열번호 2로 표시되는 염기서열인, 자연살해세포 배양방법.
- 제 2항에 있어서, 상기 mbIL-21 유전자는 서열번호 3으로 표시되는 아미노산 서열을 코딩하는 염기서열인 것인, 자연살해세포 배양방법.
- 제 5항에 있어서, 상기 서열번호 3으로 표시되는 아미노산 서열을 코딩하는 염기서열은 서열번호 4로 표시되는 염기서열인, 자연살해세포 배양방법.
- 제 2항에 있어서, 상기 OX40L 유전자는 서열번호 5로 표시되는 아미노산 서열을 코딩하는 염기서열인 것인, 자연살해세포 배양방법.
- 제 7항에 있어서, 상기 서열번호 5로 표시되는 아미노산 서열을 코딩하는 염기서열은 서열번호 6으로 표시되는 염기서열인, 자연살해세포 배양방법.
- 제 2항에 있어서, 상기 mTNF-α 유전자는 서열번호 8로 표시되는 아미노산 서열을 코딩하는 염기서열인 것인, 자연살해세포 배양방법.
- 제 9항에 있어서, 상기 서열번호 8로 표시되는 아미노산 서열을 코딩하는 염기서열은 서열번호 9로 표시되는 염기서열인, 자연살해세포 배양방법.
- 제 2항에 있어서, 상기 유전자는 재조합 렌티 바이러스를 통해 도입된 것인, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 CD4+ T세포는 4-1BBL 유전자 또는 mbIL-21 유전자가 발현되는 것인, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 CD4+ T세포는 4-1BBL 유전자 및 mbIL-21 유전자가 발현되는 것인, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 CD4+ T세포는 4-1BBL 유전자, mbIL-21 유전자 및 mTNF-α 유전자가 발현되는 것인, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 CD4+ T세포는 4-1BBL 유전자, mbIL-21 유전자, OX40L 유전자 및 mTNF-α 유전자가 발현되는 것인, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 CD4+ T세포가 Hut78, H9, Jurkat, Loucy, Molt-3, Molt-13, Peer, RPMI8402 및 TALL-01 세포로 이루어진 군으로부터 선택되는 어느 하나인 것을 특징으로 하는, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 원료세포는 제대혈(cord blood) 유래 단핵세포인 것을 특징으로 하는, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 원료세포는 CD3(+) 세포가 제거된 세포인 것을 특징으로 하는, 자연살해세포 배양방법.
- 제 1항에 있어서, 형질전환된 CD4+ T세포와 원료세포의 비율을 0.1:1 내지 50:1로 혼합하여 배양하는 것을 특징으로 하는, 자연살해세포 배양방법.
- 제 1항에 있어서, 상기 원료세포는 지지세포와 1회 혼합하여 5일 내지 60일간 배양하거나, 지지세포와 2회 이상 혼합하여 60일 이상 배양하는 것을 특징으로 하는, 자연살해세포의 배양방법.
- 제 1항에 있어서, 항-CD3 항체 및 인터루킨 단백질이 함유된 배지에서 배양하는 것을 특징으로 하는, 자연살해세포 배양방법.
- 제 21항에 있어서, 상기 항-CD3 항체는 OKT3, UCHT1 및 HIT3a로 이루어진 군으로부터 선택되는 어느 하나를 포함하는 것을 특징으로 하는, 자연살해세포 배양방법.
- 제 21항에 있어서, 상기 인터루킨 단백질은 IL-2, IL-12, IL-15, IL-18 및 IL-21로 이루어진 군으로부터 선택되는 어느 하나를 포함하는 것을 특징으로 하는, 자연살해세포 배양방법.
- 제1항의 자연살해세포 배양방법에 의해 제조된 자연살해세포.
- 형질전환된 CD4+ T세포를 유효성분으로 포함하는 자연살해세포 배양용 조성물.
- 제 25항에 있어서,상기 형질전환된 CD4+ T세포는 4-1BBL 유전자, mbIL-21 유전자, OX40L 유전자 및 mTNF-α 유전자로 구성된 군으로부터 선택되는 적어도 하나의 유전자가 발현되는 것인, 조성물.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019381526A AU2019381526B2 (en) | 2018-11-14 | 2019-11-13 | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
EP19885404.4A EP3892721A4 (en) | 2018-11-14 | 2019-11-13 | METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES |
CN201980075094.XA CN113383069A (zh) | 2018-11-14 | 2019-11-13 | 使用转化的t细胞培养脐带血来源的自然杀伤细胞的方法 |
CA3120085A CA3120085A1 (en) | 2018-11-14 | 2019-11-13 | Method for culturing cord blood-derived natural killer cells using transformed t-cells |
US17/293,835 US20240084256A1 (en) | 2018-11-14 | 2019-11-13 | Method for culturing cord blood-derived natural killer cells using transformed t-cells |
SG11202104662UA SG11202104662UA (en) | 2018-11-14 | 2019-11-13 | Method for culturing cord blood-derived natural killer cells using transformed t-cells |
JP2021526674A JP7179986B2 (ja) | 2018-11-14 | 2019-11-13 | 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 |
IL283176A IL283176A (en) | 2018-11-14 | 2021-05-13 | A method for growing blood-derived natural killer cells in culture using transduced T cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0139722 | 2018-11-14 | ||
KR20180139722 | 2018-11-14 | ||
KR1020190145068A KR102338957B1 (ko) | 2018-11-14 | 2019-11-13 | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 |
KR10-2019-0145068 | 2019-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020101361A1 true WO2020101361A1 (ko) | 2020-05-22 |
Family
ID=70730529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/015469 WO2020101361A1 (ko) | 2018-11-14 | 2019-11-13 | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020101361A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066644B2 (en) | 2018-02-01 | 2021-07-20 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
WO2022216826A1 (en) * | 2021-04-08 | 2022-10-13 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd38-targeted antibody |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
US11766456B2 (en) | 2014-11-26 | 2023-09-26 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102911918A (zh) * | 2011-12-29 | 2013-02-06 | 上海交通大学医学院 | 一种基因工程细胞及其在nk细胞扩增中的应用 |
EP2856876A1 (en) * | 2007-03-30 | 2015-04-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
KR101520534B1 (ko) * | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
KR20160063114A (ko) * | 2014-11-26 | 2016-06-03 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
-
2019
- 2019-11-13 WO PCT/KR2019/015469 patent/WO2020101361A1/ko unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2856876A1 (en) * | 2007-03-30 | 2015-04-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
CN102911918A (zh) * | 2011-12-29 | 2013-02-06 | 上海交通大学医学院 | 一种基因工程细胞及其在nk细胞扩增中的应用 |
KR101520534B1 (ko) * | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
KR20160063114A (ko) * | 2014-11-26 | 2016-06-03 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
Non-Patent Citations (7)
Title |
---|
BIOSSEL L. ET AL., BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 14, 2008, pages 1031 - 1038 |
CONDIOTTI ET AL., EXPERIMENTAL HEMATOL., vol. 29, no. 1, 2001, pages 104 - 113 |
FIAS A.M. ET AL., EXPERIMENTAL HEMATOLOGY, vol. 36, no. 1, 2008, pages 61 - 68 |
FUJISAKI ET AL., CANCER RES., vol. 69, no. 9, 2009, pages 4010 - 4017 |
GONG ET AL., TISSUE ANTIGENS, vol. 76, no. 6, 2010, pages 467 - 475 |
GOODIER ET AL., J. IMMUNOL., vol. 165, no. 1, 2000, pages 139 - 147 |
MIN, BOKYUNG: "Identification of NK cell costimulatory receptors for large-scale expansion of NK cells for adoptive immunotherapy in cancer patients", PH.D. THESIS, May 2018 (2018-05-01), Korea Advanced Institute of Science and Technology, pages 1 - 143, XP055942600 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11766456B2 (en) | 2014-11-26 | 2023-09-26 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
US11970547B2 (en) | 2017-11-14 | 2024-04-30 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
US11066644B2 (en) | 2018-02-01 | 2021-07-20 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
WO2022216826A1 (en) * | 2021-04-08 | 2022-10-13 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd38-targeted antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018217064A2 (ko) | 형질전환된 t세포를 이용한 자연살해세포의 배양방법 | |
WO2020101361A1 (ko) | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 | |
AU2016231061B2 (en) | Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients | |
WO2019182425A1 (ko) | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 | |
WO2021054789A1 (ko) | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 | |
WO2016048107A1 (ko) | 인터페론-감마 또는 인터류킨-1베타를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
WO2020197318A1 (ko) | Car 유전자가 도입된 nk 세포의 제조방법 및 그의 용도 | |
WO2018056736A1 (ko) | 신규 자연살해 세포주 및 그의 용도 | |
JP2021519107A (ja) | 膜結合型IL−10を発現する遺伝子的にリプログラミングされたTreg | |
JP2022512450A (ja) | Gpc3を標的とする免疫エフェクター細胞およびその応用 | |
WO2017146538A1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022025638A1 (ko) | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 | |
KR102338957B1 (ko) | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 | |
WO2017003153A1 (ko) | 제대혈 단핵세포 또는 이로부터 유래된 세포로부터 자연살해세포를 제조하는 방법 | |
WO2016117960A1 (ko) | 면역질환 치료 효능을 갖는 grim19이 과발현된 중간엽줄기세포 및 이의 용도 | |
WO2022255793A1 (ko) | 배양보조세포를 포함하는 자연살해세포 증식용 조성물 | |
WO2021107635A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 | |
Liu et al. | Retrogenic ICOS expression increases differentiation of KLRG-1hiCD127loCD8+ T cells during Listeria infection and diminishes recall responses | |
WO2019059713A2 (ko) | 자연살해세포의 제조방법 및 그의 용도 | |
WO2021101270A1 (ko) | 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법 | |
WO2023027471A1 (ko) | 기능이 강화된 신규 키메라 항원 수용체(car) | |
WO2022158800A1 (ko) | 면역세포 관용성 조절인자 과발현 줄기세포 및 이의 용도 | |
WO2023167575A1 (ko) | 저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포 및 이의 제조방법 | |
WO2022220648A1 (ko) | Hla-dr 특이적 키메라 항원 수용체 및 이의 용도 | |
WO2022010220A1 (ko) | 면역원성이 감소된 신규한 이식용 세포 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19885404 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021526674 Country of ref document: JP Kind code of ref document: A Ref document number: 3120085 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019381526 Country of ref document: AU Date of ref document: 20191113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019885404 Country of ref document: EP Effective date: 20210614 |